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ABSTRACT: Development of “smart” noninvasive bioimaging probes for trapping specific enzyme activities is highly 
desirable for cancer therapy in vivo. Given that β-galactosidase (β-gal) is an important biomarker for cell senescence and 
primary ovarian cancers, we design an enzyme-activatable ratiometric near-infrared (NIR) probe (DCM-βgal) for the 
real-time fluorescent quantification and trapping of β-gal activity in vivo and in situ. DCM-βgal manifests significantly 
ratiometric and turn-on NIR fluorescent signals simultaneously in response to β-gal concentration, which make it 
favorable for monitoring dynamic β-gal activity in vivo with self-calibration in fluorescent mode. We exemplify DCM-
βgal for the ratiometric tracking of endogenously overexpressed β-gal distribution in living 293T cells via the lacZ gene 
transfection method and OVCAR-3 cells, and further realize real-time in vivo bioimaging of β-gal activity in colorectal 
tumor-bearing nude mice. Advantages of our system include light-up ratiometric NIR fluorescence with large Stokes-
shift, high photo-stability, and displays pH independency under the physiological range, allowing for the in vivo real-
time evaluation of β-gal activity at the tumor site with high-resolution three-dimensional bioimaging for the first time. 
Our work provides a potential tool for in vivo real-time tracking enzyme activity in preclinical applications. 
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INTRODUCTION 
Molecular bioimaging of enzyme activity in vivo is rapidly 
emerging as a powerful strategy for accurate disease 
diagnostics.1-6 The development of “smart” noninvasive 
imaging reagents for the determination of specific enzyme 
activity in vivo is critically required for cancer diagnosis.7-15 
However, during the onset and progression of cancer, the 
dynamic living system complexity makes it difficult to 
track and visualize in vivo enzyme activity. As a typical 
enzyme, β-galactosidase (β-gal) has been demonstrated as 
an important biomarker for cell senescence and primary 
ovarian cancers.16-19 Much effort has been devoted to 
treating β-gal as an enzymatic target with ﬂuorescent 
probes to visualize its activity in preclinical diagnosis.20-25 
However, owing to the limited indirect prediction via 
histology or in vitro experiments, the currently fluorescent 
β-gal probes are not capable of precisely tracking in vivo 
real-time enzyme activity required for cancer diagnosis. 
One of the major obstacles encountered with 
ﬂuorescence imaging of enzyme activity in vivo is the 
strong intrinsic auto-ﬂuorescence background from living 
tissues, which signiﬁcantly compromises the accuracy of 
measurement under physiological conditions. Near-
infrared (NIR) ﬂuorescence imaging is an accessible tool 
for noninvasive in vivo visualization of mammalian tissues 
with decreased auto-ﬂuorescence, low light scattering and 
high penetration depth.26-34 Weissleder et al. designed 
DDAOG emitting in the NIR region for in vivo detection of 
β-gal activity,35 but severe cross-talk between the excitation 
and emission spectra weakening the ability to capture valid 
signals. Moreover, in contrast with the single wavelength 
fluorescence-intensity based systems, ratiometric 
fluorescence probes are of considerable practical 
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advantage due to enhanced signal-to-background ratio, in 
which the detectable ratio signal can be obtained by two 
independent read-out channels of activated versus 
unreacted probes resulting in improved and reliable signal 
quantification.36-40  
 
Scheme 1. Proposed Sensing Mechanism for β-Gal 
Enzymatic Activation of DCM-βgal. 
 
The aforementioned concerns encourage us to create a 
novel fluorescent probe for tracking the in vivo behavior of 
the important β-gal enzyme and clarifying its potential role 
in tumor diagnosis. Our strategy is based on grafting an 
enzyme-active trigger onto a controllable emissive, bright 
and photostable NIR chromophore. Controllable emission 
with large spectral shifts via modulation of the electron 
donor ability of novel NIR-active fluorophores is critical 
and required for excellent imaging contrast agents. Herein, 
we report on a β-gal-targeting ratiometric and light-up NIR 
fluorescent probe (DCM-βgal, Scheme 1), in which the 
dicyanomethylene-4H-pyran (DCM) chromophore is 
utilized as a NIR fluorescence reporter,41-45 and a β-gal 
cleavable unit as the enzyme-active trigger. As expected, 
the emission wavelength is distinctly changed upon 
removal of the β-gal-responsive group (the enzyme-
triggered moiety, Scheme 1), resulting in a new broad 
emission band in the NIR region. The system enables the 
direct and accurate monitoring of intracellular 
endogenous β-gal distribution in transfection living cells 
with a high signal-to-noise ratio. That in turn allows for 
real-time in vivo bioimaging of β-gal activity in colorectal 
tumor-bearing nude mice. Probe DCM-βgal possesses 
several striking characteristics, such as ratiometric 
fluorescence activation with a light-up NIR emission and 
high photo-stability in physiological range. To the best of 
our knowledge, DCM-βgal is the first light-up NIR 
fluorescence probe for the in vivo and in situ tracking β-gal 
activity in tumor-bearing nude mice using high-resolution 
three-dimensional fluorescence imaging. 
 
RESULTS AND DISCUSSION 
Design and Synthesis. NIR-active fluorophores are 
favored for in vivo optical imaging contrasts. As well-
known laser dyes, DCM derivatives could perform 
controllable emission in the NIR region with large spectral 
shifts via tuning electron donor ability,41-46 which offer such 
critical features as excellent imaging contrasts. Specifically, 
DCM-OH has favorable donor–π–acceptor (D–π–A) 
characteristics for sensor design, with a phenolic group for 
regulating electron donating capability. The emission 
wavelength could be distinctly changed upon removing the 
substituted group (for instance, the enzyme-triggered 
moiety, Scheme 1). In this regard, we designed probe DCM-
βgal by grafting a β-gal activatable unit onto DCM-OH 
moiety. The synthetic route for the probe was depicted in 
the Supporting Information (SI). DCM-βgal was finally 
synthesized with a yield of 33% under mild conditions, 
which was fully characterized by 1H and 13C NMR, and 
HRMS (SI). 
Spectroscopic Properties and Optical Response to 
β-Gal. To test the validity of this probe, the spectral 
properties of DCM-βgal were investigated with β-gal in 
physiological buffer solution. DCM-βgal shows a typical 
broad absorption band at 440 nm from its intrinsic 
intramolecular charge transfer (ICT). Upon titration with 
12 U β-gal, the absorption peak of DCM-βgal at 440 nm 
decreased, and a concomitant new absorption peak 
appeared at about 535 nm (Figure 1A), which is in perfect 
accordance with the absorption of DCM-Oˉ (Figures S1 and 
S2 in SI). The well-defined isosbestic point at 450 nm 
clearly demonstrates the coexistence of DCM-βgal and the 
cleavage product (DCM-Oˉ). The color change from faint 
yellow to rose red allows the colorimetric detection of β-
gal using the naked eye, which is invoked by a large red 
shift of ca. 100 nm in the absorption spectra. 
As expected, the emission profiles of DCM-βgal are 
correlated to those of the absorption profiles in the 
presence of β-gal. When excited at the isosbestic point of 
450 nm, an obvious ratiometric fluorescent signal (I685 
nm/I500 nm) was observed. As shown in Figure 1B, a new broad 
band falling into the emission range of 550-800 nm sharply 
increased, along with a decrease in the emission band at 
500 nm. Upon excitation of the new absorption peak at 535 
nm, a remarkable NIR fluorescence enhancement was 
observed with a peak at 685 nm (Figure 1C and Table S1 in 
SI). Clearly, the new distinct large red-shift fluorescence 
response confirms that β-gal-mediated hydrolysis of DCM-
βgal liberates the oxygen atom as a strong electron donor 
in the D–π–A structure, thereby increasing ICT and 
shifting the emission maximum to the NIR region.  
Figure 1D depicts the ratiometric fluorescent signal (I685 
nm/I500 nm) as a function of time. It takes about 35 min to 
reach a plateau, which is also directly reflected by the 
fluorescence response at 685 nm (Figure S3 in SI). The 
kinetic results imply that the fluorescent response can be 
utilized for the rapid detection of β-gal, which is much 
faster than that of previously reported FDG (3 h).47 
Therefore, in our subsequent experimental assays, the 
detection limit was set at 35 min. Specifically, when the 
probe was incubated with 12 U β-gal for ca. 35 min, a 14-
fold increase was observed in the fluorescence ratio of I685 
nm/I500 nm (Figure 1B), or a 34-fold fluorescence 
enhancement at 685 nm was observed (Figure 1C). Notably, 
the plot of the I685 nm/I500 nm ratio or I685 nm against the 
concentrations of β-gal ranging from 0 to 12 U both display 
a good linear relationship (Inset of Figures 1B and 1C). 
Hence, the linear curve of the I685 nm/I500 nm ratio allows for 
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the convenient quantitative detection of β-gal very 
convenient over this concentration range. The Michaelis 
constant (Km) of DCM-βgal in the β-gal-catalyzed reaction 
was calculated to be 60.1 μM (Table S2 in SI), which was 
much lower than that of commercial X-gal (260.6 μM). 
Obviously, DCM-βgal shows higher affinity to β-gal than 
X-gal. Furthermore, derived from the change in 
concentration-dependent ratio, the detection limit of 
DCM-βgal was calculated as 1.7 × 10-4 U mL-1, indicative of 
ultra-sensitivity to changes in β-gal expression (Figure S4 
in SI). Consequently, DCM-βgal enables the fast and 
quantitative ratiometric fluorescence detection of β-gal. 
 
Figure 1. Spectral profiles of DCM-βgal (10 μM) incubation with β-gal (12 U) in aqueous solution (PBS/DMSO = 7:3, v:v, pH = 7.4, 
37 oC): (A) Time dependence of absorption spectra. Inset: images before and after treatment with β-gal; (B) Time dependence of 
emission spectra (0-35 min), λex = 450 nm. Inset: the relationship between I685 nm/I500 nm and β-gal concentration; (C) Emission 
spectra of DCM-βgal upon addition of β-gal (0-12 U), λex = 535 nm. Inset: the relationship between I685 nm and β-gal concentration; 
(D) Time dependence of I685 nm/I500 nm for DCM-βgal in the presence (red) and absence (blue) of β-gal, λex = 450 nm.  
 
Sensing Mechanism. For taking insight into the 
activation of DCM-βgal with enzyme, a series of 
experiments were also carried out. The HPLC results 
confirmed that DCM-βgal is a substrate of β-gal, which 
exclusively generates DCM-Oˉ (Figure S5 in SI). In the ESI-
MS spectra of DCM-βgal with β-gal, the peaks of DCM-βgal 
and DCM-Oˉ were found at m/z 497.1441 and 311.0697 
(Figure S6 in SI), respectively. In fact, the aforementioned 
spectra from the reaction of DCM-βgal with β-gal resemble 
those of DCM-Oˉ, which also strongly supports the fact 
that the enzyme-triggered cleavage reaction causes the 
release of free DCM-Oˉ. All these observations confirm 
that DCM-βgal can be hydrolyzed by breaking the C-O 
bond upon enzyme-reactive reaction with β-gal to release 
an electron-rich aglycon, DCM-Oˉ, which emits in the NIR 
region and possesses a distinct ratiometric fluorescent 
signal with a large spectral shift. 
To test the interference with other biological analytes, 
the reactivity of DCM-βgal towards a variety of enzyme 
species, amino acids and biomolecules was examined. 
There were only subtle changes in fluorescence ratio upon 
the addition of 100 equiv of cellulase, reductase, lysozyme, 
esterase, cysteine, homocysteine, glutathione, 
dithiothreitol, hydrogen peroxide and hydrogen sulfide. 
However, only when treated with β-gal was the large and 
distinct enhancement of fluorescence ratio (I685 nm/I500 nm) 
observed (Figure 2A), accompanying by an obvious color 
change from faint yellow to rose red (Figure 2B), which 
corresponds to the evolution of DCM-Oˉ. These results 
demonstrate the excellent selectivity of DCM-βgal towards 
β-gal over other competitive analytes, which is required in 
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order to achieve accurate detection under practical 
applications. 
 
 
Figure 2. (A) Fluorescence ratio (I685 nm/I500 nm) responses and 
(B) color changes of DCM-βgal (10 μM) to various analytes in 
aqueous system (PBS/DMSO = 7:3, v:v; pH = 7.4, 37 oC). Bars 
correspond to the fluorescence ratio (I685 nm/I500 nm) of DCM-
βgal with 100 equivalent of analytes, λex = 450 nm. (C) Time-
dependent fluorescence intensity of ICG (10 μM, monitored at 
812 nm, and λex = 780 nm), DCM-OH (10 μM, monitored at 565 
nm, and λex = 450 nm), and DCM-βgal (10 μM, monitored at 
525 nm, and λex = 450 nm) under sustained illumination. 
 
Photo-Stability. The high photo-stability of DCM-βgal 
and DCM-OH is highly desirable to perform long time in 
vivo tracking enzyme activity in preclinical applications. 
Here the photo-stability of DCM-βgal and DCM-OH was 
evaluated by time-course fluorescence measurements 
upon sustained illumination in aqueous solution. The 
commercially FDA-approved NIR dye ICG was chosen as a 
control. After exposure to high density light (Hamamatsu, 
LC8 Lightningcure, 300 W) for about 60 s, the fluorescence 
intensity of ICG was reduced to a minimum value, 
indicating that ICG was almost completely decomposed, 
however, 90% of the DCM-βgal and DCM-OH fluorescence 
intensity remained under the same conditions. Indeed, the 
fluorescence half-life of the DCM-βgal was 35-fold longer 
than that of ICG (Figure 2C). The photo-stability of both 
DCM-βgal and DCM-OH is much better than ICG, which 
is a critical factor for the long time tracking and bioimaging 
in vivo. 
pH Profiles of DCM-βgal and DCM-OH. pH is an 
important factor on the photophysical properties of the 
sensing probe. We subsequently evaluated the pH 
dependence of the emission profiles of DCM-OH and 
DCM-βgal (Figure S7 in SI). There was negligible 
fluorescence change at 685 nm for DCM-βgal during the 
pH range from 3.5 to 9.8 upon excitation at 535 nm. 
Obviously, the fluorescence of DCM-βgal remains silent 
over the physiological pH range. More excitingly, the 
hydrolytic product of DCM-βgal can only be produced at 
the optimal physiological pH range. That is, the pKa of 
DCM-OH was measured to be ca. 7.1 which allows DCM-
βgal to favorably exploit the physiological conditions of 
living systems. 
Ratiometric Imaging of Endogenous β-Gal in Living 
Cells. We further explored whether DCM-βgal could be 
used for the ratiometric tracking and imaging of 
endogenous β-gal activity in living cells. As a high efficient 
and facile transfection process, human embryonic kidney 
cells (293T cells) were chosen as model cell lines. In order 
to generate endogenous β-gal in living cells, lacZ gene was 
introduced into 293T cells by employing a gene 
transfection method to overexpress β-gal. The MTT assay 
results indicate that both DCM-βgal and its hydrolysate 
DCM-OH have minimal toxicity and enjoy superior 
biocompatibility toward cultured cell lines (Figure S8 in SI). 
After incubation with DCM-βgal (10 μM) at 37 oC for 30 min, 
the lacZ-(-) 293T cells without overexpressed β-gal 
exhibited both bright fluorescence in green channel and 
little fluorescence in the red channel (Figures 3B and 3C), 
which corresponds to the two peaks (525 and 685 nm) in 
the emission spectra of DCM-βgal. In contrast, the lacZ-(+) 
293T cells with overexpressed β-gal exhibited a decreased 
fluorescence in green channel, and an concomitant 
increase in the red channel (Figures 3I and 3J), 
corresponding to formation of DCM-Oˉ. The ratiometric 
imaging of endogenous β-gal activity was constructed from 
red and green channels (Fred/Fgreen, Figures 3D and 3K). The 
average emission ratio Fred/Fgreen of the lacZ-(-) and lacZ-(+) 
293T cells was calculated to be 0.43 and 2.20, respectively. 
An approximate 5-fold increase in ratio for the lacZ-(+) 
compared to lacZ-(-) 293T cells was observed (Figure S8 in 
SI). Therefore, we have successfully demonstrated the 
quantitative ratiometric imaging of endogenous β-gal 
activity. 
Moreover, upon excitation at 560 nm, a clear 
fluorescence image was captured in the overexpressed 
lacZ-(+) 293T cells in the NIR region due to the liberation 
of DCM-Oˉ by intracellular β-gal, while a fluorescent signal 
was barely observed for the lacZ-(-) 293T cells (Figures 3F 
and 3M). Moreover, OVCAR-3 from human ovarian cancer 
patients that has been demonstrated overexpression of 
endogenous β-gal19,25,48 was also chosen as another cell 
lines model. As expected, the same as in living 293T cells 
via the lacZ gene transfection method, we also clearly 
observed the quantitative ratiometric and light-up NIR 
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imaging of endogenous β-gal activity in OVCAR-3 cells 
(Figures 3O-3U). As shown in Figure 3A1, the light-up 
fluorescence signals were sharply decreased in the 
presence of a competitive β-gal inhibitor (D-galactose)49. 
These results further confirmed that DCM-βgal could 
monitor endogenous β-gal activity. Notably, since the 
incubation of DCM-βgal was processed without any other 
complex loading techniques, DCM-βgal has been 
demonstrated to be highly cell membrane-permeable and 
photo-stable. These results suggested that DCM-βgal can 
be specifically activated in β-gal-expressing cells, thereby 
providing a ratiometric and light-up NIR readout for the in 
situ quantitative tracking and visualization of endogenous 
β-gal activity in living cells. 
 
Figure 3. Confocal and ratiometric images of 293T and OVCAR-3 cells incubated with DCM-βgal (10 μM) for 30 min: (A-G) lacZ-
(-) 293T cells without overexpressed β-gal, (H-N) lacZ-(+) 293T cells with overexpressed β-gal, (O-U) OVCAR-3 cells, and (V-B1) 
OVCAR-3 cells pretreated with inhibitor for 30 min. Green channel obtained from 490-530 nm, red channel obtained from 650-
720 nm, and ratiometric images generated from red and green channel, λex = 404 nm. NIR fluorescence images obtained from 605-
725 nm, λex = 560 nm. The ratiometric images were obtained by the image analysis software, Image Pro-plus 6.0. 
 
 
Figure 4. Biodistribution of avidin-β-gal targeting to LoVo 
tumor-bearing mice in vivo. Avidin-β-gal (100 μg) in PBS was 
intravenously injected into LoVo-implanted mice, and the 
mouse was sacrificed after 18 h. The main internal organs 
(tumor, spleen, stomach, lung, kidney, muscle, liver, heart, 
intestine, and bone) were removed and stained with X-gal 
(0.04 mg mL-1) for another 2.5 h. 
 
Real-time in vivo Imaging of β-Gal Activity in 
Tumors. The current fluorescent probes for imaging of β-
gal activity are not very suitable for in vivo experiments 
because their emissions are not located in NIR region,20-23 
and thus fail to penetrate deeper tissue and are 
complicated by intrinsic auto-ﬂuorescence background 
signals. Recently, Urano et al. have made important 
progress by developing HMRef-βGal for in vivo 
fluorescence endoscopy of β-gal activity.25 Inspired by the 
distinct “light-up” NIR emission, we next examined its 
capability for real-time in vivo visualization of β-gal activity 
in tumors. A commercial tumor targeting reagent (avidin-
β-gal) was initially applied to localize β-gal to tumor 
growth of human colorectal cancer LoVo cell xenografts in 
vivo by intravenous injection50,51 since avidin has high 
affinity for lectins on the surface of LoVo cells.52,53 We next 
examined whether avidin-β-gal could be targeted to tumor 
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cells in vivo by intravenous injection. After injection for 18 
h, the main internal organs were obtained by anatomy and 
stained with X-gal (0.04 mg mL-1), a commercial detection 
reagent for β-gal. After incubation for another 2.5 h, only 
in the disseminated tumor was a blue precipitate observed, 
suggesting that avidin-β-gal can be efficiently targeted to 
LoVo tumor cells in vivo without loss of the enzymatic 
activity (Figure 4). The mice bearing subcutaneously 
implanted tumors were administered DCM-βgal by 
intravenous or intratumoral injection, and then scanned at 
different time points with an IVIS Lumina Kinetic Series III 
imaging system. 
 Owing to amplified fluorescence signals by enzymatic 
turnover and particular low background interference in 
NIR region, the remarkable NIR fluorescent signal was 
observed in the tumor site after in situ injection of DCM-
βgal (0.0375 mg kg-1, Figure 5A) for β-gal upregulating mice 
induced by intravenous injection of avidin-β-gal (100 μg). 
It should be noted that after merely 5 min post injection, 
the NIR fluorescence signal was already clearly appreciated 
in tumor, indicative of the rapid activation of DCM-βgal 
and the fluorescence intensity gradually increased and 
reached a maximum level after 3 h post injection, then 
slowly decayed as the time increased. In comparison, for 
the unpretreated tumor-bearing mouse, there is minimal 
light-up fluorescence under the same conditions (Figure 
5B). To further confirm that the NIR fluorescent signal 
comes from the cleavage of DCM-βgal by β-gal in the 
tumor, we also recorded the ex vivo fluorescence images of 
tumor and other normal organs collected immediately 
after sacrificing the mice with upregulating β-gal at 3 h post 
injection. In consistent with the in vivo results, only the 
tumor was fluorescent (Figure 5C). As expected, the 
fluorescence images of other normal organs and tumor 
gained from the control mice displayed no fluorescence 
signal (Figure 5D).  
Real-time three-dimensional imaging is a powerful tool 
for accurate disease diagnostics, particular for suspicious 
lesions with high spatiotemporal precision. The preferable 
characteristics of DCM-βgal with light-up NIR 
performance and rapid response to β-gal activity (5 min) at 
the lesion site make it suitable to perform real-time three-
dimensional imaging. After post-injection of the probe into 
the mice containing abundant β-gal, we obtained the real-
time high-resolution three-dimensional fluorescence 
image with an IVIS Spectrum CT imaging system. 
Observed from different perspective in real time, the 
tumor site was precisely located in vivo and in situ with the 
help of NIR light-up fluorescence signals (Figure 5E and 
Movie 1 in SI). By contrast, in the control experiments, 
there was no fluorescence signal located in tumors (Figure 
S10 and Movie 2 in SI). For the first time, we exemplify the 
in situ three-dimensional fluorescence imaging to visualize 
real-time in vivo β-gal activity in tumors. 
 
Figure 5 (A and B) In vivo imaging of β-gal activity in tumor-bearing nude mice after tumor-injection, (C and D) fluorescence 
images of the main internal organs after anatomy, and (E) three-dimensional in vivo imaging of β-gal activity in tumor-bearing 
nude mice after tumor-injection of DCM-βgal for 3 h: (A, C and E) avidin-β-gal (100 μg) in PBS was intravenously injected into 
LoVo-implanted mice, and after 18 h DCM-βgal was then injected into the mice, (B and D) tumor-bearing mice were not pretreated 
with avidin-β-gal before injection of DCM-βgal acting as the control. 
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CONCLUSIONS 
We have developed a ratiometric and light-up NIR 
fluorescent probe DCM-βgal, composed of the DCM 
scaffold as a typical NIR fluorescence reporter and a β-gal 
cleavable unit as the enzyme-active trigger. The probe has 
higher photo-stability than commercial ICG, and displays 
pH independency over the physiological range. DCM-βgal 
displays higher affinity for β-gal than commercial X-gal 
and much faster response to β-gal than the previously 
reported FDG. More importantly, this probe was 
successfully applied for in situ and in vivo visualization of 
β-gal activity in human colorectal tumor in mice model, as 
well as real-time trapping of intracellular endogenous β-gal 
distribution in over-expressed living 293T cells via the lacZ 
gene transfection method. For the first time in vivo real-
time capture of β-gal activity at tumor site with high-
resolution three-dimensional view was performed. In light 
of its simplicity, sensitivity and biocompatibility, this 
ratiometric and light-up enzyme-activatable NIR 
fluorescent probe provides an accessible tool for the 
unprecedented quantification and trapping of β-gal 
activity in vivo for human colorectal cancer diagnosis.  
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